T. Rowe Price Associates’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $267K | Sell |
|
|||||
|
2025
Q2 | $237K | Buy |
|
|||||
|
2025
Q1 | $189K | Hold |
|
|||||
|
2024
Q4 | $306K | Sell |
|
|||||
|
2024
Q3 | $161K | Hold |
|
|||||
|
2024
Q2 | $154K | Buy |
|
|||||
|
2024
Q1 | $137K | Buy |
|
|||||
|
2023
Q4 | $114K | Sell |
|
|||||
|
2023
Q3 | $890K | Buy |
|
|||||
|
2023
Q2 | $508K | Buy |
|
|||||
|
2023
Q1 | $385K | Buy |
|
|||||
|
2022
Q4 | $736K | Sell |
|
|||||
|
2022
Q3 | $742K | Buy |
|
|||||
|
2022
Q2 | $531K | Buy |
|
|||||
|
2022
Q1 | $544K | Sell |
|
|||||
|
2021
Q4 | $470K | Sell |
|
|||||
|
2021
Q3 | $589K | Sell |
|
|||||
|
2021
Q2 | $737K | Buy |
|
|||||
|
2021
Q1 | $734K | Buy |
|
|||||
|
2019
Q4 | – | Sell |
|
|||||
|
2019
Q3 | $34K | Buy |
|
|||||
|
2019
Q2 | $68K | Buy |
|
|||||
|
2019
Q1 | $63K | Buy |
|
|||||
|
2017
Q4 | – | Sell |
|
|||||
|
2017
Q3 | $8.78M | Sell |
|
|||||
|
2017
Q2 | $11.1M | Buy |
|
|||||
|
2017
Q1 | $10.3M | Buy |
|